CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab.

Laura Nisenbaum,Robert Martone,Tianle Chen,Rajasimhan Rajagovindan,Gersham Dent,John Beaver,Carrie Rubel,Annie Racine,Ping He,Katie Harrison,Robert Dean,Manu Vandijck,Samantha Budd Haeberlein

Alzheimer's & dementia : the journal of the Alzheimer's Association（2023）

引用 0|浏览15

暂无评分

摘要

CSF biomarkers and amyloid PET concordance were assessed in Ph3 aducanumab trials. Robust concordance between CSF biomarkers and amyloid PET was observed. CSF biomarker ratios increased diagnostic accuracy over single CSF biomarkers. CSF Aβ42/Aβ40 demonstrated high concordance with amyloid PET. Results support CSF biomarker testing as a reliable alternative to amyloid PET.

查看译文

关键词

Alzheimer's disease,EMERGE,ENGAGE,amyloid beta,biomarker,cerebrospinal fluid,concordance analysis,positron emission tomography,tau

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要